BRCA1 and breast cancer: The TNT study of metastatic or recurrent locally advanced TNBC or BRCA 1/2 mutated breast cancer showed that taxanes and carboplatin were comparably well tolerated in both groups, and that carboplatin was beneficial in BRCA1/2 mutated subgroup [51].